We are live on ! Find out more
IRWD icon

Ironwood Pharmaceuticals
IRWD

Fund managers haven’t disclosed any holdings of IRWD yet.

IRWD Hedge Fund Activity: Q1 2026 in Review

226 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q1 2026, worth a combined $567M — up 8.9% from $520M a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new IRWD positions and 25 closed out — a net gain of 31 holders — while 86 added to existing stakes and 56 trimmed.

The largest buyer was State Street, adding an estimated $12.5M. The largest seller was Sarissa Capital Management, cutting an estimated $27.6M.

  • 226 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q1 2026, up from 199 in Q4 2025.
  • Funds reported $567M of Ironwood Pharmaceuticals stock for Q1 2026, up 8.9% quarter-over-quarter.
  • 56 funds opened new Ironwood Pharmaceuticals positions in Q1 2026 and 25 closed out, a net change of +31 holders.
  • The largest Ironwood Pharmaceuticals buyer in Q1 2026 was State Street, an estimated $12.5M added.
  • The largest Ironwood Pharmaceuticals seller in Q1 2026 was Sarissa Capital Management, an estimated $27.6M sold.

Based on aggregated 13F filings for Q1 2026.